- Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
- Cellectis modifie sa note convertible de 20 millions de dollars dans le cadre de l’accord de collaboration avec son partenaire Cytovia Therapeutics
- Calyxt et Cibus annoncent la signature d’un Accord de Fusion
- Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
- Monthly information on share capital and company voting rights
- Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
- Cellectis met en place un programme At the Market sur le Nasdaq
- Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
- Mayflower Bioventures lance sa première spin-off, Primera Therapeutics, en collaboration avec Cellectis pour développer une plateforme d'édition du génome pour traiter les maladies mitochondriales
- Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
More ▼
Key statistics
As of last trade Cellectis SA (ZVA:BER) traded at 2.17, 6.28% above its 52-week low of 2.04, set on Dec 08, 2022.
52-week range
Markit short selling activity
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 2.17 |
Average volume | -- |
---|---|
Shares outstanding | 45.68m |
Free float | 45.57m |
P/E (TTM) | -- |
Market cap | 133.37m EUR |
EPS (TTM) | -2.11 EUR |
Data delayed at least 15 minutes, as of Dec 13 2022 07:04 GMT.
More ▼